◇ Compound Reference
Thymosin Beta-4 · 5mg
Synthetic fragment of thymosin beta-4. Promotes vascular scaffolding, cellular migration, and structural tissue repair.
Thymosin Beta-4 · 5mg per vial · dispensed after a physician review.
Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.
TB-500 is a synthetic peptide fragment of Thymosin Beta-4, a 43-amino-acid protein found in nearly all human cells with the exception of red blood cells. The peptide promotes cellular migration, angiogenesis, and tissue repair through actin sequestration.
Binds to G-actin, forming a 1:1 complex that inhibits actin polymerization, regulating cytoskeletal dynamics during cell migration and tissue remodeling. Also upregulates VEGF and stimulates endothelial cell migration.
Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05
These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.
Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.
Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.
| Class | Synthetic thymosin β4 fragment |
| Studied mechanism | Actin regulation; angiogenesis and cell-migration pathways in preclinical models |
| Human pharmacokinetics | Not well-characterised in peer-reviewed human literature |
| Evidence base | Predominantly preclinical |
| Form | Lyophilized powder, reconstituted under clinical protocol |
| Regulatory status | Not an approved therapy; physician-supervised use only |
TB-500 is a synthetic fragment of Thymosin β4, with reproducible preclinical evidence in cardiac and angiogenesis contexts. WADA-prohibited (S2). No human RCT for the fragment specifically.
Preclinical · Mouse Model. Landmark study showing that Thymosin β4 (the parent peptide of TB-500) administered to mouse hearts after coronary artery ligation activated integrin-linked kinase, promoted cardiomyocyte migration and survival, and improved cardiac function. Established TB4 as a candidate for cardiac repair research. The findings are preclinical (mouse); they catalysed subsequent human-cardiac TB4 research that has not yet produced definitive outcome trials.
View on publisher ↗Preclinical · Mouse Model. Demonstrated that systemic Thymosin β4 mobilises adult epicardial progenitor cells and induces neovascularization in mouse models of cardiac injury. Showed stimulated migration of resident endothelial cells, accelerated localised angiogenesis, reduced myocardial scar/fibrosis, and preserved cardiac ejection fraction. Together with Bock-Marquette 2004, this paper established the strongest preclinical case for TB4 as a cardiac-repair candidate. Direct human-cardiac RCT translation has not occurred; ophthalmic and dermal-wound human trials of TB4 (not the TB-500 fragment) exist.
View on publisher ↗In Vitro & Mechanistic Review. Mechanistic review and supporting laboratory data characterising Thymosin β4 as a G-actin sequestering molecule. Identified roles in endothelial cell migration and angiogenesis in wound-healing models. Findings remain primarily preclinical; controlled human trial evidence specific to the TB-500 fragment is limited.
View on publisher ↗TB-500 is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.
Are you 18 years of age or older?